JP2014532665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532665A5 JP2014532665A5 JP2014539143A JP2014539143A JP2014532665A5 JP 2014532665 A5 JP2014532665 A5 JP 2014532665A5 JP 2014539143 A JP2014539143 A JP 2014539143A JP 2014539143 A JP2014539143 A JP 2014539143A JP 2014532665 A5 JP2014532665 A5 JP 2014532665A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- liposome
- combination according
- subject
- mol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 claims description 29
- 150000002632 lipids Chemical class 0.000 claims description 26
- 239000002105 nanoparticle Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 11
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 8
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 150000003431 steroids Chemical class 0.000 claims description 8
- 239000000411 inducer Substances 0.000 claims description 7
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 6
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 6
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 6
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 6
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 4
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 4
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 claims description 4
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical group OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 claims description 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 4
- 229960001756 oxaliplatin Drugs 0.000 claims description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- -1 cationic lipid Chemical class 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 239000007928 intraperitoneal injection Substances 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- 239000013066 combination product Substances 0.000 claims 2
- 229940127555 combination product Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 description 23
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553786P | 2011-10-31 | 2011-10-31 | |
| US61/553,786 | 2011-10-31 | ||
| PCT/US2012/062635 WO2013066903A1 (en) | 2011-10-31 | 2012-10-31 | Combinational liposome compositions for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017044663A Division JP6549172B2 (ja) | 2011-10-31 | 2017-03-09 | がん治療用組合せリポソーム組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014532665A JP2014532665A (ja) | 2014-12-08 |
| JP2014532665A5 true JP2014532665A5 (enExample) | 2015-09-24 |
| JP6143767B2 JP6143767B2 (ja) | 2017-06-07 |
Family
ID=47146747
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539143A Expired - Fee Related JP6143767B2 (ja) | 2011-10-31 | 2012-10-31 | がん治療用組合せリポソーム組成物 |
| JP2017044663A Expired - Fee Related JP6549172B2 (ja) | 2011-10-31 | 2017-03-09 | がん治療用組合せリポソーム組成物 |
| JP2018218127A Pending JP2019023243A (ja) | 2011-10-31 | 2018-11-21 | がん治療用組合せリポソーム組成物 |
| JP2019088222A Pending JP2019123753A (ja) | 2011-10-31 | 2019-05-08 | がん治療用組合せリポソーム組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017044663A Expired - Fee Related JP6549172B2 (ja) | 2011-10-31 | 2017-03-09 | がん治療用組合せリポソーム組成物 |
| JP2018218127A Pending JP2019023243A (ja) | 2011-10-31 | 2018-11-21 | がん治療用組合せリポソーム組成物 |
| JP2019088222A Pending JP2019123753A (ja) | 2011-10-31 | 2019-05-08 | がん治療用組合せリポソーム組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9370489B2 (enExample) |
| EP (2) | EP3424564A1 (enExample) |
| JP (4) | JP6143767B2 (enExample) |
| KR (1) | KR20140097215A (enExample) |
| CN (1) | CN104023793B (enExample) |
| BR (1) | BR112014010291A2 (enExample) |
| CA (1) | CA2852564A1 (enExample) |
| ES (1) | ES2694154T3 (enExample) |
| IL (2) | IL232344B (enExample) |
| MX (1) | MX360391B (enExample) |
| RU (1) | RU2640934C2 (enExample) |
| WO (1) | WO2013066903A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8920775B2 (en) * | 2009-07-17 | 2014-12-30 | Technical University Of Denmark | Loading technique for preparing radionuclide containing nanoparticles |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| PL4332576T3 (pl) | 2013-03-15 | 2025-09-08 | Translate Bio, Inc. | Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane |
| JP2014227338A (ja) * | 2013-05-17 | 2014-12-08 | キヤノン株式会社 | インドシアニングリーン含有粒子およびその製造方法 |
| CA2928568A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| DK3138555T3 (da) | 2014-04-30 | 2020-12-14 | Fujifilm Corp | Liposomsammensætning og fremgangsmåde til fremstilling heraf |
| CA2976526A1 (en) * | 2015-02-13 | 2016-08-18 | Trendmed Co., Ltd. | Compositions and methods of tumor treatment utilizing nanoparticles |
| WO2016141161A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| WO2016141167A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
| US20180243217A1 (en) * | 2015-03-17 | 2018-08-30 | Leon-Nanodrugs Gmbh | Nanoparticles comprising a stabilized boronic acid compound |
| WO2016161428A1 (en) * | 2015-04-02 | 2016-10-06 | The Research Foundation For The State University Of New York | Serum-stable compositions and methods for light-triggered release of materials |
| DK3350157T3 (da) | 2015-09-17 | 2022-02-14 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler |
| ES2869283T3 (es) | 2015-11-02 | 2021-10-25 | Fujifilm Corp | Agente terapéutico antitumoral que contiene composición de liposoma de gemcitabina y kit |
| WO2017087685A1 (en) | 2015-11-20 | 2017-05-26 | The Regents Of The University Of California | Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
| MD3386484T2 (ro) | 2015-12-10 | 2022-11-30 | Modernatx Inc | Compoziții și metode de livrare a unor agenți terapeutici |
| WO2017104840A1 (ja) * | 2015-12-18 | 2017-06-22 | メディギア・インターナショナル株式会社 | 生体分解性腫瘍封止剤 |
| AU2016377681B2 (en) | 2015-12-22 | 2021-05-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| KR101630397B1 (ko) * | 2015-12-31 | 2016-06-24 | 한국과학기술원 | 항암제-인도시아닌 그린-리포좀 복합체를 포함하는 암 치료용 조성물 |
| WO2017142876A1 (en) | 2016-02-15 | 2017-08-24 | University Of Georgia Research Foundation, Inc. | lPA-3-LOADED LIPOSOMES AND METHODS OF USE THEREOF |
| AU2017268175B2 (en) | 2016-05-16 | 2023-02-23 | Access To Advanced Health Institute | PEGylated liposomes and methods of use |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| CN106474057A (zh) * | 2016-12-02 | 2017-03-08 | 中国药科大学 | 一种奥沙利铂热敏长循环脂质体的蔗糖溶液制剂及其制备方法 |
| SG10202107836SA (en) * | 2017-01-18 | 2021-08-30 | Temasek Life Sciences Laboratory Ltd | Hyperstabilized liposomes increase targeting of mitotic cells |
| AU2018234692B2 (en) | 2017-03-15 | 2022-06-02 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| ES2911186T3 (es) | 2017-03-15 | 2022-05-18 | Modernatx Inc | Formas cristalinas de aminolípidos |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| US10925831B2 (en) * | 2017-08-28 | 2021-02-23 | Wake Forest University | Liposomal formulations of platinum-acridine anticancer agents and methods thereof |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| WO2019084290A1 (en) * | 2017-10-25 | 2019-05-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF PHARMACEUTICAL AGENTS |
| US10606661B2 (en) * | 2017-12-15 | 2020-03-31 | Rubrik, Inc. | On-demand provisioning of customized developer environments |
| JP7364561B2 (ja) | 2018-06-20 | 2023-10-18 | 富士フイルム株式会社 | ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP4509118A3 (en) | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| EP3890775A1 (en) * | 2018-12-06 | 2021-10-13 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
| RU2706427C1 (ru) * | 2018-12-27 | 2019-11-19 | Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" | Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата |
| JP7253735B2 (ja) | 2019-07-02 | 2023-04-07 | パナソニックＩｐマネジメント株式会社 | 通過可否判定装置、通過管理システム、通過可否判定方法、及び、コンピュータプログラム |
| CN114514015B (zh) | 2019-09-19 | 2025-01-07 | 丹麦科技大学 | 免疫刺激胶束组合物 |
| CA3154618A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| WO2021062042A1 (en) * | 2019-09-24 | 2021-04-01 | Pataigin, Llc | Methods for determining growth and response |
| CN110571005B (zh) * | 2019-09-27 | 2021-01-01 | 广西科技大学 | 一种固定化金属离子-磁性脂质体及其制备方法和应用 |
| EP4199906A1 (en) * | 2020-08-20 | 2023-06-28 | Bionanosim (BNS) Ltd | Lipid delivery systems for delivery of oxaliplatin palmitate acetate |
| KR102560135B1 (ko) | 2020-12-04 | 2023-07-27 | 가톨릭대학교 산학협력단 | 표적 치료제의 효과적인 전달을 위한 다기능성 리포좀 조성물 |
| WO2022171777A1 (en) | 2021-02-12 | 2022-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for prognosis and treating a patient suffering from cancer |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| JP2024509938A (ja) | 2021-03-08 | 2024-03-05 | アイジーン インコーポレイテッド | ＳＡＲＳ－ＣｏＶ－２予防用ワクチン組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023087A (en) * | 1986-02-10 | 1991-06-11 | Liposome Technology, Inc. | Efficient method for preparation of prolonged release liposome-based drug delivery system |
| CA2252055C (en) | 1996-04-11 | 2007-01-16 | The University Of British Columbia | Fusogenic liposomes |
| US6897196B1 (en) | 2001-02-07 | 2005-05-24 | The Regents Of The University Of California | pH sensitive lipids based on ortho ester linkers, composition and method |
| US7273620B1 (en) * | 2002-05-20 | 2007-09-25 | University Of British Columbia | Triggered release of liposomal drugs following mixing of cationic and anionic liposomes |
| US7149468B2 (en) | 2002-07-25 | 2006-12-12 | The Mcgraw-Hill Companies, Inc. | Methods for improving certainty of test-taker performance determinations for assessments with open-ended items |
| WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| AU2003239511A1 (en) * | 2003-05-20 | 2004-12-13 | Aronex Pharmaceuticals, Inc. | Combination chemotherapy comprising a liposomal platinum complex |
| EP1695696A1 (en) * | 2003-12-01 | 2006-08-30 | Mitsubishi Pharma Corporation | Liposome |
| TWI262798B (en) * | 2003-12-31 | 2006-10-01 | Ind Tech Res Inst | Liposome and drug deliver system |
| US20110020434A1 (en) | 2005-09-02 | 2011-01-27 | O'halloran Thomas V | Nanoparticle arsenic-platinum compositions |
| WO2007049279A2 (en) * | 2005-10-26 | 2007-05-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A liposomal combination and uses thereof |
-
2012
- 2012-10-31 ES ES12783805.0T patent/ES2694154T3/es active Active
- 2012-10-31 EP EP18189596.2A patent/EP3424564A1/en not_active Withdrawn
- 2012-10-31 CA CA2852564A patent/CA2852564A1/en not_active Abandoned
- 2012-10-31 KR KR1020147014027A patent/KR20140097215A/ko not_active Ceased
- 2012-10-31 EP EP12783805.0A patent/EP2773426B1/en not_active Not-in-force
- 2012-10-31 JP JP2014539143A patent/JP6143767B2/ja not_active Expired - Fee Related
- 2012-10-31 US US13/664,457 patent/US9370489B2/en not_active Expired - Fee Related
- 2012-10-31 CN CN201280064482.6A patent/CN104023793B/zh not_active Expired - Fee Related
- 2012-10-31 WO PCT/US2012/062635 patent/WO2013066903A1/en not_active Ceased
- 2012-10-31 BR BR112014010291A patent/BR112014010291A2/pt not_active Application Discontinuation
- 2012-10-31 RU RU2014120216A patent/RU2640934C2/ru not_active IP Right Cessation
- 2012-10-31 MX MX2014004960A patent/MX360391B/es active IP Right Grant
-
2014
- 2014-04-29 IL IL232344A patent/IL232344B/en active IP Right Grant
-
2016
- 2016-05-23 US US15/162,072 patent/US9717686B2/en not_active Expired - Fee Related
-
2017
- 2017-03-09 JP JP2017044663A patent/JP6549172B2/ja not_active Expired - Fee Related
- 2017-07-28 US US15/663,472 patent/US10213385B2/en not_active Expired - Fee Related
-
2018
- 2018-04-16 IL IL258740A patent/IL258740B/en unknown
- 2018-11-21 JP JP2018218127A patent/JP2019023243A/ja active Pending
-
2019
- 2019-02-19 US US16/279,977 patent/US20190175505A1/en not_active Abandoned
- 2019-05-08 JP JP2019088222A patent/JP2019123753A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532665A5 (enExample) | ||
| RU2014120216A (ru) | Комбинационные липосомальные композиции для лечения рака | |
| JP2015515992A5 (enExample) | ||
| JP2019023243A5 (enExample) | ||
| AU2013274101B2 (en) | Compositions for treating cancer and methods for making the same | |
| JP2014523444A5 (enExample) | ||
| JP2016529284A5 (enExample) | ||
| JP2015519383A5 (enExample) | ||
| JP2013526545A5 (enExample) | ||
| JP2016513651A5 (enExample) | ||
| IL278079B2 (en) | Inhalable liposomal sustained release composition for use in treating pulmonary diseases | |
| JP2016505545A5 (enExample) | ||
| CL2013003621A1 (es) | Composición farmacéutica inhalable que comprende una dispersión de partículas liposomales que contienen un agente bioactivo hidrófobo, tal como coq10, un fosfolípido, y un vehículo de dispersión acuosa, apta para aerosolización continua; método de preparación; método de administración; uso para tratar enfermedades del pulmón. | |
| CN108024960A (zh) | 含有阴离子药物的药物组合物及其制备方法 | |
| JP2015530387A5 (enExample) | ||
| JP2011521913A (ja) | 薬剤送達のためのリポソームおよびその調製方法 | |
| HK1252369A1 (zh) | 利用纳米颗粒治疗肿瘤的组合物和方法 | |
| WO2012042024A1 (en) | Self-assembling nanoparticles for the release of bisphosphonates in the treatment of human cancers | |
| JP2013505204A (ja) | ｓＰＬＡ２加水分解性リポソームの医学的使用 | |
| JP2018527335A5 (enExample) | ||
| JP2016094425A5 (enExample) | ||
| WO2020071349A1 (ja) | 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬 | |
| JPWO2019209787A5 (enExample) | ||
| Orthmann et al. | Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes | |
| JP2010507580A5 (enExample) |